CollPlant Biotechnologies Ltd. (CLGN)

Compare

2.4600

-0.1500

(-5.75%)

At close: April 3 at 4:00:00 PM EDT

2.5000

+0.04

+(1.63%)

After hours: April 3 at 5:18:32 PM EDT

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven?

CollPlant Biotechnologies Ltd. ( NASDAQ:CLGN ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. 6 days ago

CLGN
-5.75%
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.

PR Newswire 8 days ago

CLGN
-5.75%
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its

PR Newswire 15 days ago

CLGN
-5.75%
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of ten

PR Newswire last month

CLGN
-5.75%
CollPlant Biotechnologies Provides a Corporate Update

CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update.

PR Newswire last month

CLGN
-5.75%
US Penny Stocks To Watch In January 2025

As the U.S. stock market navigates mixed performance amid fluctuating interest rate expectations and economic data releases, investors are keenly observing potential opportunities in various sectors. Penny stocks, often representing smaller or emerging companies, continue to attract attention due to their potential for significant value creation when supported by strong financials. Despite being an older term, penny stocks remain relevant for those seeking to uncover promising investments in...

Simply Wall St. 2 months ago

TRVG

LSTA

CLGN
-5.75%
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter ending September 30, 2024, and provided a corporate update.

PR Newswire 4 months ago

CLGN
-5.75%
US Penny Stocks With Market Caps Under $3B

Stocks in the United States have recently taken a breather following a post-election rally, with major indices like the Dow Jones Industrial Average and S&P 500 experiencing slight declines after reaching record highs. Amidst this backdrop, investors continue to explore diverse opportunities across various market segments. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite their somewhat outdated label. These stocks can offer surprising...

Simply Wall St. 4 months ago

CLGN
-5.75%
PERF

PERF-WS
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate upd

PR Newswire 4 months ago

CLGN
-5.75%
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

CLGN
-5.75%
Even after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three years

This week we saw the CollPlant Biotechnologies Ltd. ( NASDAQ:CLGN ) share price climb by 10%. But the last three years...

Simply Wall St. 7 months ago

CLGN
-5.75%
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

PR Newswire 7 months ago

CLGN
-5.75%
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd. (Nasdaq: SSYS) today announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin® 3D printer.

PR Newswire 7 months ago

SSYS

CLGN
-5.75%
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial statements and corporate

PR Newswire 7 months ago

CLGN
-5.75%
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023.

PR Newswire 8 months ago

CLGN
-5.75%
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks. In addition, CollPlant announced additiona

PR Newswire 9 months ago

CLGN
-5.75%
CollPlant Biotechnologies First Quarter 2024 Earnings: Misses Expectations

CollPlant Biotechnologies ( NASDAQ:CLGN ) First Quarter 2024 Results Key Financial Results Revenue: US$98.0k (down 77...

Simply Wall St. 9 months ago

CLGN
-5.75%
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.

PR Newswire 9 months ago

CLGN
-5.75%
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates

PR Newswire 10 months ago

CLGN
-5.75%
CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 11 months ago

CLGN
-5.75%

Performance Overview

Return	CLGN	S&P 500 (^GSPC)
YTD	-31.67%	-8.25%
1-Year	-54.90%	+3.55%
3-Year	-78.02%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CollPlant Biotechnologies Ltd. (CLGN)

When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven?

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

CollPlant Biotechnologies Provides a Corporate Update

US Penny Stocks To Watch In January 2025

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

US Penny Stocks With Market Caps Under $3B

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth

Even after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three years

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report

CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data

CollPlant Biotechnologies First Quarter 2024 Earnings: Misses Expectations

CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (NASDAQ:CLGN) Is In A Strong Position To Grow Its Business

Performance Overview